Adverse Effects

Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series

Volumn , Issue , 2008, Pages 433-448

  Loke, Yoon K ^a   Price, Deirdre ^b   Herxheimer, Andrew ^c,d  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c DIPEx ^*  (United Kingdom)

^d UK COCHRANE CENTRE   (United Kingdom)

Author keywords

'all inclusive' and publicity biased avoidance trade off; Adverse effect search strategy; Adverse effects assessing strategy; Adverse effects consideration; Adverse events case reports; Case control and cohort studies; Clinical trial risk of bias assessment; Trial report outcome measure withdrawal or drop out

Indexed keywords

EID: 84890757019     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470712184.ch14     Document Type: Chapter

References (27)

1. Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. European Journal of Clinical Pharmacology 2001; 57: 89-91.
2. Asaria P, MacMahon E. Measles in the United Kingdom: can we eradicate it by 2010? BMJ 2006; 333: 890-895.
3. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291: 2457-2465.
4. Derry S, Kong LY, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Medical Research Methodology 2001; 1: 7.
5. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. Journal of Pain and Symptom Management 1999; 18: 427-437.
6. Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ 2004; 328: 39-41.
7. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ 2007; 334: 349-351.
8. Golder S, McIntosh HM, Duffy S, Glanville J, Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Information and Libraries Journal 2006; 23: 3-12.
9. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews 2002, Issue 2. Art No: CD001520.
10. Ioannidis JPA, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004; 141: 781-788.
11. Jick H. The discovery of drug-induced illness. New England Journal of Medicine 1977; 296:481-485.
12. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet 2004; 364: 2021-2029.
13. Kelly WN. The quality of published adverse drug event reports. Annals of Pharmacotherapy 2003; 37: 1774-1778.
14. Koch-Weser J, Sellers EM, Zacest R. The ambiguity of adverse drug reactions. European Journal of Clinical Pharmacology 1977; 11: 75-78.
15. Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clinical Pharmacology and Therapeutics 1995; 58:692-698.
16. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. British Journal of Clinical Pharmacology 2004; 57: 616-621.
17. Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions-systematic literature survey of follow-up. BMJ 2006; 332: 335-339.
18. McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Medical Research Methodology 2004; 4: 19.
19. Miettinen OS. The need for randomization in the study of intended effects. Statistics in Medicine 1983; 2: 267-271.
20. Olsen H, Klemetsrud T, Stokke HP, Tretli S, Westheim A. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Pressure 1999; 8: 94-101.
21. Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. Canadian Medical Association Journal 2006; 174: 635-641.
22. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. The Lancet 2002; 359: 696-700.
23. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 329: 44-47.
24. Vandenbroucke JP. When are observational studies as credible as randomised trials? The Lancet 2004; 363: 1728-1731.
25. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? Canadian Medical Association Journal 2006; 174: 645-646.
26. Venning GR. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. British Medical Journal (Clinical Research Edition) 1982; 284: 249-252.
27. Venning GR. Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays? British Medical Journal (Clinical Research Edition) 1983; 286: 365-368.